PURIGEN BIOSYSTEMS - Key Persons

Job Titles:

• CEO of Sestina Bio

Bill W. Colston, Ph.D. CEO of Sestina Bio Dr. Bill Colston was previously the CEO and scientific founder of QuantaLife Inc., a successful biotechnology startup company. QuantaLife developed the most accurate genetic analysis system in the world, now sold internationally (droplet digital PCR™). Dr. Colston raised multiple rounds of private funding, moving from concept to manufactured product in a fraction of the time of comparable companies in this space. QuantaLife grew exponentially during his tenure, from the four scientific founders during the inception in 2008 to over sixty employees by the time it was sold to BioRad in 2011. Prior to QuantaLife, Dr. Colston worked within the University of California (UC) National Labs for almost 20 years, ultimately serving in multiple different senior leadership roles. A prolific scientific writer and inventor, he has authored numerous publications and patents. Dr. Colston received his BS in biology from the University of Texas, Austin, in 1989 and his Ph.D. in biomedical engineering from the University of California, Davis, in 1997.

Job Titles:

• SVP of Sales and Marketing

Chris Grimley SVP of Sales and Marketing Chris Grimley brings over 25 years of experience in the life science industry to his role at Purigen. Prior to joining Purigen Mr. Grimley was Vice President of Marketing at Labcyte Inc. (acquired by Beckman Life Sciences), and prior to that Vice President of Marketing at NanoString Technologies during which time the company completed its IPO. Mr. Grimley has also served as Senior Director of Marketing at Agilent Technologies, managing the company's genomics portfolio which included microarray, target enrichment and molecular biology reagents product lines. Mr. Grimley began his career at Applied Biosystems (now part of Thermo Fisher Scientific) where he held positions of increasing responsibility including Director of Marketing for the company's real-time PCR instrument portfolio. Mr. Grimley holds a Bachelor of Science degree in Biochemistry from San Francisco State University.

Job Titles:

• CSO, Tecan Genomics

Doug Amorese, Ph.D. CSO, Tecan Genomics Dr. Douglas Amorese has led Research and Development teams in the commercialization of systems that automated/integrated molecular biology methods for over 34 years. In his 10 years at DuPont, he led teams that introduced a fluorescent sequencing system employing single reaction dye terminator chemistry (1987) as well as an automated Southern blot generation and processing system for microbial identification (1994). In 1996 he joined Hewlett Packard/Agilent. As R&D manager for the BioScience Products Division, his teams developed microarray fabrication, processing, scanning and analysis methods for 2 color gene expression and comparative genomic hybridization (CGH) studies. In 2008, he was appointed VP of R&D at NuGEN Technologies where he led the transformation of the company from providing products for microarray processing to next generation sequencing (NGS). When NuGEN was acquired by Tecan he became Chief Scientific Officer for Tecan Genomics. He is an inventor on 24 issued U.S. patents and numerous foreign equivalents. Dr. Amorese graduated from Colgate University in 1976, and received his Ph.D. from Colorado State University in 1982.

Job Titles:

• Research Fellow - Agilent
• Research Fellow at Agilent Technologies

Dr. Jeffrey Sampson is a Research Fellow at Agilent Technologies where he focuses on Agilent's longer-term strategic opportunities. Dr. Sampson leads a diverse team of highly skilled professionals concentrating on applying physics, chemistry and biochemistry to advance life science measurement, intellectual property assessment, competitive market analysis as well as technical evaluation in support of Agilent licensing and acquisition opportunities. Additionally, Dr. Sampson is a co-founder of Agilent's venture capital program where he currently leads opportunity evaluation and technical diligence. He has over 20 US patents in the fields of DNA and RNA synthesis and measurement and synthetic biology methods. Dr. Sampson holds a BS in chemistry from Butler University, a Ph.D. in biochemistry from the University of Illinois and a Postdoc and Senior Research Fellow at the California Institute of Technology.

Job Titles:

• Executive Chairman of the Board of Directors
• Venture Partner at 5AM Ventures

Joe Victor joined the Purigen Biosystems board at their Series A funding in March of 2016. Mr. Victor is also a Venture Partner at 5AM Ventures, a leading venture capital firm with offices in San Francisco and Boston focused on building next-generation life science companies. He is currently Executive Chairman on the boards of 5AM portfolio companies Biodesy and Precision Nanosystems, and is on the boards of Glencoe Software and RareCyte. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Prior to joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company. Mr. Victor also served as CEO of DVS Sciences (acquired by Fluidigm), and Applied Precision (acquired by GE Healthcare). Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Job Titles:

• Co - Founder
• Scientific Advisor

Juan Santiago, Ph.D. Scientific Advisor and Co-founder Juan Santiago received his MS and PhD in Mechanical Engineering from the University of Illinois at Urbana-Champaign in 1995. His research includes the development of microsystems for on-chip chemical and biochemical analysis, methods for sample preparation, and electric-field based deionization methods. Applications of this work include molecular diagnostics, drug discovery, and the production of drinking water. He is a Fellow of the American Physical Society, a Fellow of the American Society of Mechanical Engineering, and a Fellow of the American Institute for Medical and Biological Engineering. He is an Editorial Advisory Board of the journal Analytical Chemistry, and an Associate Editor of the journal Microfluidics and Nanofluidics. He is co-founder of several companies in the microfluidics area, co-inventor of micron-resolution particle image velocimetry (Micro-PIV), and director of the Stanford Microfluidics Laboratory. He has served as Associate Editor of the journal Lab on a Chip ('08-'13). Santiago has given more than 30 keynote and named lectures and more than 150 additional invited lectures. As one measure of impact, his work is cited about 1500 times per year (Google Scholar h index of 65). He has graduated 27 PhD students and advised eight postdoctoral researchers. 19 of his former advisees are now professors at major universities. He has authored and co-authored over 160 archival publications and 200 conference papers, and holds 47 patents (24 of which are currently licensed).

Job Titles:

• Co - Founder
• CSO

Klint Rose, Ph.D. CSO and Co-founder Dr. Klint Rose co-founded Purigen Biosystems in 2012. Dr. Rose was previously an R&D Manager at QuantaLife, Inc. (acquired by Bio-Rad), where he played a key leadership role in the development, launch, and support of their droplet digital PCRTM product. He previously directed a portfolio of several successful projects at Lawrence Livermore National Laboratory (LLNL) with applications in sample preparation, desalination, and nanomanufacturing. Dr. Rose is an expert in microfluidics and electrokinetics, with over 15 years of experience in the space. Klint received his B.S. and M.S. in mechanical engineering from the Massachusetts Institute of Technology (MIT) and his Ph.D. from Stanford University.

Job Titles:

• Founding Partner - 5AM Ventures

Scott M. Rocklage, Ph.D. Founding Partner - 5AM Ventures Scott M. Rocklage, PhD joined 5AM Ventures in 2003 as a Venture Partner, became a Managing Partner in 2004 and transitioned to Founding Partner in 2017. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®). He has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (acquired by Vifor Pharma), Novira (acquired by J&J), Aprea (NASDAQ: APRE), Cidara (NASDAQ: CDTX), Albamunity and Halio. He currently serves as Board Chairman of Expansion and is a Board member at NodThera and Nouscom. He was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor of over 35 U.S. patents and has produced more than 100 peer-reviewed publications. Dr. Rocklage is based in the Boston, MA office.

Job Titles:

• Assistant Professor of Pathology, Stanford University

Sean C. Bendall, Ph.D. Assistant Professor of Pathology, Stanford University Sean C. Bendall is an Assistant Professor in the Department of Pathology at Stanford University, School of Medicine. His research specialty is the development and application of single-cell proteomic tools for the investigation of human systems. Growing up and attending university in Canada, Sean's Ph.D. in biochemistry and stem cell biology dissected protein regulators of human pluripotency using embryonic stem cells and mass spectrometry-based proteomics. Then at Stanford University, he trained with Professor Garry Nolan, pioneering single cell CyTOF mass cytometry and multiplexed ion beam imaging (MIBI) - both next-generation single-cell proteomic analysis platforms. Sean's work in mass cytometry analysis has gone on to provide an unparalleled granularity of understanding in multiple facets of human hematopoiesis and immunology. His lab continues to unravel the nature of both ‘healthy and dysfunctional' early human hematopoietic immune cell biology using single cell proteomic analysis. His work has been recognized by numerous awards including the Damon Runyon Cancer Research Foundation "Breakthrough Scientist" Award, the International Society for the Advancement of Cytometry President's Award of Excellence, and the NIH Common Fund "New Innovator" Award.

Job Titles:

• Senior Investment Director - Roche Venture Fund

Job Titles:

• Consulting CFO

brings over 30 years of financial and operational experience to his role at Purigen. Mr. Reichenbach was the CFO at Flow International for 13 years before joining Applied Precision Inc., which was acquired by GE Healthcare. Mr. Reichenbach holds a BA in finance from the University of Washington.